Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;3(5):201-10.
doi: 10.1177/2040622312454045.

The case for more intensive use of statins

Jordan Fulcher  1 , Anthony Keech
Affiliations

The case for more intensive use of statins

Jordan Fulcher et al. Ther Adv Chronic Dis. 2012 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Relation between proportional reduction in incidence of major coronary events and major vascular events and mean absolute low-density lipoprotein (LDL) cholesterol reduction at 1 year. Squares represent a single trial plotted against mean absolute LDL cholesterol reduction at 1 year, with vertical lines above and below corresponding to one stand error (SE) of unweighted event rate reduction. Trials are plotted in order of magnitude of difference in LDL cholesterol difference at 1 year. For each outcome, regression line (which is forced to pass through the origin) represents weighted event rate reduction per mmol/liter LDL cholesterol reduction. (Reproduced from Baigent et al. [2005] with permission). Reprinted from The Lancet, Vol. 366, Cholesterol Treatment Trialists’ (CTT) Collaborators, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Page No. 1271, Copyright 2005, with permission from Elsevier.
Figure 2.
Figure 2.
Effects on any major vascular event in each study. In the left panel, unweighted rate ratios (RRs) for each trial of the comparison of first event rates between randomly allocated treatment groups are plotted along with 99% confidence intervals (CIs). Trials are ordered according to the absolute reduction in low-density lipoprotein (LDL) cholesterol (LDL-C) at 1 year within each type of trial comparison (more versus less statin and statin versus control). In the right panel, RRs are weighted per 1.0 mmol/liter LDL-C difference at 1 year. Subtotals and totals with 95% CIs are shown by open diamonds. (Reproduced from Baigent et al. [2010] with permission). Reprinted from The Lancet, Vol. 376, Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Page No. 1673, Copyright 2010, with permission from Elsevier.
Figure 3.
Figure 3.
Effects on major vascular events per 1.0 mmol/liter reduction in low-density lipoprotein (LDL) cholesterol (LDL-C), by baseline LDL-C concentration on the less intensive or control regimen. Rate ratios (RRs) are plotted for each comparison of first event rates between treatment groups, and are weighted per 1.0 mmol/liter LDL-C difference at 1 year. Analyses were done with trial-specific and subgroup-specific LDL weights for each baseline LDL-C category. Missing data are not plotted. RRs are shown with horizontal lines denoting 99% confidence intervals (CIs) or with open diamonds showing 95% CIs. (Reproduced from Baigent et al. [2010] with permission). Reprinted from The Lancet, Vol. 376, Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Page No. 1676, Copyright 2010, with permission from Elsevier.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abraha I., Bonacini I., Montedori A., Abraha I., Bonacini I., Montedori A. (2006) Efficacy and safety of cholesterol-lowering treatment. Lancet 367: 469; author reply 470–471 - PubMed
    1. Alsheikh-Ali A., Ambrose M., Kuvin J., Karas R. (2005) The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111: 3051–3057 - PubMed
    1. Alsheikh-Ali A., Karas R. (2007) Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration Adverse Event Reporting System). Am J Cardiol 99: 379–381 - PubMed
    1. Alsheikh-Ali A., Maddukuri P., Han H., Karas R., Alsheikh-Ali A., Maddukuri P., et al. (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50: 409–418 - PubMed
    1. Alsheikh-Ali A., Trikalinos T., Kent D., Karas R., Alsheikh-Ali A., Trikalinos T., et al. (2008) Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 52: 1141–1147 - PubMed

LinkOut - more resources